Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7...
Source: Merck.com - Research and Development News - December 18, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Chromophobe renal cell carcinoma with concomitant sarcomatoid transformation
Chromophobe renal cell carcinoma is the third most common form of adult renal epithelial neoplasm. A sarcomatoid component occurs in approximately 8% of all chromophobe renal cell carcinoma cases, while metaplastic bone formation is extremely rare.12/14/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2013 Category: Cancer & Oncology Source Type: news

Findings on Carcinomas Reported by Investigators at University of Texas
"We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma. In this randomised, double-blind, multicentre, phase 2 study, patients were enrolled from 49 hospitals and outpatient clinics in the Czech Republic, Germany, Japan, Russia, Spain, and USA. Patients with treatment-naive metastatic renal-cell carcinoma received axitinib 5 mg twice daily during a 4 week lead-in period..."12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

First-Line Inlyta Active in Metastatic Kidney Cancer
First-line therapy with Inlyta® (axitinib) demonstrated clinical activity in metastatic renal cell carcinoma, according to the results of a study published in The Lancet Oncology.12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

Low sodium levels linked to poor targeted therapy outcomes
Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate.12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

Early tumor shrinkage predicts targeted therapy efficacy
Early tumor shrinkage in patients with metastatic renal cell carcinoma (mRCC) following vascular endothelial growth factor (VEGF)-targeted therapy may herald good long-term survival, research shows.12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

Predicting outcome for high-dose IL-2 therapy
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission;..12/11/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 11, 2013 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma Development and miRNAsRenal Cell Carcinoma Development and miRNAs
The majority of renal cell carcinoma cases are detected accidentally, and often at a late stage. Could miRNAS serve as potential biomarkers for diagnosis and prognosis? Pharmacogenomics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Early tumor shrinkage predicts targeted therapy efficacy in RCC
Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news

Low sodium levels linked to poor targeted therapy outcomes in RCC
Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news

Clinical heterogeneity of Xp11 translocation renal cell carcinoma
Impact of fusion subtype, age, and stage12/09/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 8, 2013 Category: Cancer & Oncology Source Type: news

Cystic partially regressed clear cell renal cell carcinoma
A potential mimic of multilocular cystic renal cell carcinoma12/07/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 7, 2013 Category: Cancer & Oncology Source Type: news

Targeted Tx Fails 2 Tests in Metastatic Renal Cancer
(MedPage Today) -- A mammalian target of rapamycin (mTOR) inhibitor failed to improve outcomes in metastatic renal cell carcinoma (RCC) as compared with other therapeutic options, according to two randomized trials. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 5, 2013 Category: Urology & Nephrology Source Type: news

Predicting outcome for cancer patients receiving high-dose IL-2 therapy
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond favorably to this treatment prior to side effect onset. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 3, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

VEGF Receptor Tyrosine Kinase Inhibitors in Metastatic RCCVEGF Receptor Tyrosine Kinase Inhibitors in Metastatic RCC
Recent metastatic renal cell carcinoma clinical trial results have implications for management of patients. Find out more. Therapeutic Advances in Medical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases
OBJECTIVE: To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy.11/29/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 29, 2013 Category: Cancer & Oncology Source Type: news

Presurgical therapy with axitinib
for advanced renal cell carcinoma: a case report11/25/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 25, 2013 Category: Cancer & Oncology Source Type: news

Senate passes bill for stricter regulation of compounding pharmacies
Pastor Joey Butler, the beloved Blue Springs minister whose faith inspired thousands, has died at age 51. Suffering with renal cell cancer...11/21/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 21, 2013 Category: Cancer & Oncology Source Type: news

Papillary renal cell carcinoma
A clinical, radiologic, and pathologic study of 34 cases.11/18/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 18, 2013 Category: Cancer & Oncology Source Type: news

Why study Nivolumab?
Nivolumab is an investigational compound being studied as a potential treatment option for lung cancer, renal cell carcinoma (kidney cancer), and melanoma.11/15/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 16, 2013 Category: Cancer & Oncology Source Type: news

Kidney cancer: Vascular wall margins have little impact on cancer outcomes
In a study of 256 patients treated surgically for renal cell carcinoma (RCC) with venous thrombus at the University of Texas MD Anderson Cancer Center between 1993 and 2009, median recurrence-free interval was significantly shorter in patients with positive vascular margins (22.1 months vs 70.2 months). However, although tumour invasion into the vein wall at the resection margin was independently predictive of local recurrence, multivariable analysis revealed that it had minimal effect on systemic recurrence or cancer-specific survival.11/06/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2013 Category: Cancer & Oncology Source Type: news

Stage and grade dominate RCC outcomes
Tumor grade and American Joint Committee on Cancer stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma. (Source: MedWire News - Urology)
Source: MedWire News - Urology - November 4, 2013 Category: Urology & Nephrology Source Type: news

Characterizing late recurrence of renal cell carcinoma
Very few studies have followed patients with renal cell carcinoma for long enough to characterize late relapses. Newly published research suggests that late-recurring tumours are more likely to be of low nuclear grade and show a better response...10/30/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2013 Category: Cancer & Oncology Source Type: news

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker
in metastatic renal cell carcinoma (mRCC).10/30/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2013 Category: Cancer & Oncology Source Type: news

Differentiation of oncocytoma from chromophobe renal cell carcinoma
Standard treatment of renal neoplasms remains surgical resection, and nephrectomy for localised renal cell carcinoma (RCC) still has the best chance of cure with excellent long-term results. For smaller renal masses, especially stage T1a tumours less than 4 cm, nephron-sparing surgery is often employed. However, small incidentally detected renal masses pose an important diagnostic dilemma...10/30/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2013 Category: Cancer & Oncology Source Type: news

Cruciferous Vegetables Intake Is Associated with Lower Risk of Renal Cell Carcinoma
Evidence from a Meta-Analysis of Observational Studies10/29/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2013 Category: Cancer & Oncology Source Type: news

Comparison of baseline quality of life measures between renal cell carcinoma patients
To compare demographics, pathologic features, performance scores, comorbidities, symptoms and responses to quality of life (QoL) surveys between nephron-sparing surgery (NSS) and radical nephrectomy (RN) patients prior to surgical intervention.10/23/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 23, 2013 Category: Cancer & Oncology Source Type: news

Stage and grade dominate RCC outcomes
Tumor grade and American Joint Committee on Cancer stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma (RCC).10/23/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 23, 2013 Category: Cancer & Oncology Source Type: news

P400 predicts RCC outcome
Reduced expression of a senescence-associated protein is associated with worse outcome in patients with renal cell carcinoma (RCC), study findings show.10/23/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 23, 2013 Category: Cancer & Oncology Source Type: news

Curis and Debiopharm Group Announce Initiation of Phase I Dose Finding Clinical Study
Designed to Target Advanced Metastatic Renal Cell Carcinoma, the Study Will Determine the Maximum Tolerated Dose of Debio 0932 in Combination With Everolimus.10/23/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 23, 2013 Category: Cancer & Oncology Source Type: news

Prognostic factors could aid RCC metastasectomy decisions
Researchers have identified four factors that are associated with survival time in patients who undergo metastasectomy for metastatic renal cell carcinoma. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 22, 2013 Category: Cancer & Oncology Source Type: news

P400 predicts RCC outcome
Reduced expression of a senescence-associated protein is associated with worse outcome in patients with renal cell carcinoma, study findings show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 22, 2013 Category: Cancer & Oncology Source Type: news

Stage and grade dominate RCC outcomes
Tumor grade and American Joint Committee on Cancer stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 22, 2013 Category: Cancer & Oncology Source Type: news

NCCN Collaborates with Pfizer on Program Focused on Health Care Quality Improvement and Education
NCCN and Pfizer will elicit proposals for quality improvement and education in rare cancer types; Grants to provide funding for approximately nine proposals focused on patients with renal cell carcinoma or hematologic malignancies FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) is collaborating with Pfizer Independent Grants for Learning & Change (IGLC) to establish a peer-reviewed grant program to elicit proposals focused on heal... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - October 17, 2013 Category: Cancer & Oncology Source Type: news

NCCN Collaborates With Pfizer on Program Focused on Health Care Quality
NCCN and Pfizer Will Elicit Proposals for Quality Improvement and Education in Rare Cancer Types; Grants to Provide Funding for Approximately Nine Proposals Focused on Patients With Renal Cell Carcinoma...10/15/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 15, 2013 Category: Cancer & Oncology Source Type: news

ECC: Everolimus Effective in Advanced Papillary Renal Cell Carcinoma
The mTOR inhibitor everolimus showed clinical efficacy for the initial treatment of advanced papillary renal cell carcinoma, according to the phase II results of the RAPTOR trial. (Source: Cancer Network)
Source: Cancer Network - October 8, 2013 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma Outcome Calculator
"What are my chances of survival?"10/07/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 7, 2013 Category: Cancer & Oncology Source Type: news

Metastatic site impacts survival in targeted RCC treatment
Bone and liver metastases may have the heaviest impact on the survival of patients receiving targeted therapy for metastatic renal cell carcinoma, suggest data from the International Metastatic Renal Cell Carcinoma Database Consortium. (Source: MedWire News - Urology)
Source: MedWire News - Urology - October 7, 2013 Category: Urology & Nephrology Source Type: news

Omeros Unlocks Six Additional Class A Orphan GPCRs and Identifies Small Molecules Targeting Two Commercially Validated Class B GPCRs
The CRA detects receptor antagonists, agonists and inverse agonists. Omeros has announced that it has identified and confirmed sets of compounds that interact selectively with 52 orphan receptors linked to metastatic melanoma and lung cancer (GPR19), renal cell carcinoma...10/04/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2013 Category: Cancer & Oncology Source Type: news

New treatments aim to combat renal cell cancer and melanoma
Renal cell cancer vaccines Immatics Biotechnologies' cancer vaccine IMA901 is currently in phase III trials for the first-line treatment of metastatic renal cell cancer. The drug, which was shown to have a positive safety profile in its single-arm Phase II trial, is expected to gain approval in the US and five major EU markets* by 2015. It's estimated that IMA901 will be worth $88m by 2022, but is likely to face competition from Argos therapeutics/Kyowa HakkoKirin's AGS-003 which is currently at the same stage of development... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news

Phase 1b Study of TRC105 in Patients With Metastatic Renal Cell Carcinoma
TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced the initiation of dosing in a clinical trial evaluating the combination of TRC105 and axitinib.09/24/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 24, 2013 Category: Cancer & Oncology Source Type: news

Amendment to renal cancer TNM staging proposed
Patients with pT3a renal cell carcinoma have markedly worse survival rates if they have both fat invasion and renal vein thrombosis, rather than just one of these factors, a study shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - September 24, 2013 Category: Cancer & Oncology Source Type: news

Immune marker prognostic after non-clear cell RCC surgery
The preoperative neutrophil-to-lymphocyte ratio is associated with disease-free survival in patients undergoing resection of localized non-clear cell renal cell carcinoma, research shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - September 24, 2013 Category: Cancer & Oncology Source Type: news

Inflammatory marker may highlight aggressive RCC treatment need
Patients with metastatic renal cell carcinoma who have high preoperative levels of the inflammatory marker C-reactive protein may need intensive multimodal treatment to optimize their survival, say researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - September 24, 2013 Category: Cancer & Oncology Source Type: news

Metastatic site impacts survival in targeted RCC treatment
Bone and liver metastases may have the heaviest impact on the survival of patients receiving targeted therapy for metastatic renal cell carcinoma, suggest data from the International Metastatic Renal Cell Carcinoma Database Consortium. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - September 24, 2013 Category: Cancer & Oncology Source Type: news

Evolution of Care in Advanced Kidney Cancer
With seven targeted therapies approved for metastatic renal cell carcinoma (RCC), researchers and drug developers are now focusing on understanding the best way to sequence these therapies...09/20/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 20, 2013 Category: Cancer & Oncology Source Type: news

Revisiting the orthopaedic management of metastatic renal cell carcinoma
The rationale for a more aggressive approach09/16/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 16, 2013 Category: Cancer & Oncology Source Type: news

Tivozanib Fails to Show Overall Survival Difference in Metastatic RCC
The results of the study comparing Aveo’s tivozanib to sorafenib for the treatment of metastatic renal cell carcinoma showed no improvement in overall survival, the basis for the FDA’s rejection of the company’s new drug application earlier this year. (Source: Cancer Network)
Source: Cancer Network - September 16, 2013 Category: Cancer & Oncology Source Type: news

Collision Renal Cell Papillary and Medullary Carcinoma in a 66-Year-Old Man
The patient is a 66-year-old male who presented to his primary care physician with a 3-week history of painless gross hematuria. He underwent a renal ultrasound that showed a left kidney mass. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news

Second-line pazopanib effective in advanced RCC
Pazopanib demonstrated activity as a second-line treatment in patients with metastatic clear cell renal cell carcinoma who underwent first-line single-agent treatment with sunitinib or bevacizumab, according to results of a phase 2 trial.09/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 12, 2013 Category: Cancer & Oncology Source Type: news